Fundraise

Metir PLC

22 December 2025

 

 

THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR AN INVITATION TO ACQUIRE OR DISPOSE OF ANY SECURITIES. ATTENTION IS ALSO DRAWN TO THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

 

22 December 2025

Metir plc

("Metir", the "Group" or the "Company")

Fundraise

Metir plc (AIM: MET), the leading global provider of fast response mobile and point-of-use water and environmental testing technology, is pleased to announce the successful completion of a fundraise (the "Fundraise"), arranged by the Company's Joint Broker Turner Pope Investments Limited ("TPI"), to raise up to £1,000,000, before expenses, to support the continuing growth of the Company by way of a placing of 133,333,333 new Ordinary Shares of 0.001 pence each in the Company ("Ordinary Shares") with investors ("Placing Shares"; together the "Placing") at a price of 0.75p (the "Placing Price") per ordinary share. In connection with the Placing, the Company will issue 133,333,333 warrants to investors on the basis of one (1) warrant for every one (1) Placing Share. Each warrant entitles the holder to subscribe for one additional Ordinary Share at an exercise price of 1.5p (representing a 100% premium to the Placing Price), exercisable for a period of 24 months from the date of issuance (the "Investor Warrants").

Use of proceeds

As announced in the trading update on 2 December 2025, the cost base of the Company remains very tightly controlled and is supporting strong growth but management believes that this growth is being constrained by sub-optimal levels of working capital. The Board believes that additional financing would support stronger growth and move the Company into profitability more quickly.

The net proceeds of the Fundraise are intended to provide capital to accelerate growth of the business and move towards profitability including for the following purposes:

·    Increasing production capacity of Microtox® LX and FX instruments and Sulphate Reducing Bacteria (SRB) kits to meet growing customer demand, reduce delivery times and support improved manufacturing efficiency and margins.

·    Providing additional working capital to support inventory build, manufacturing scale-up and the conversion of the Company's growing order book into revenue.

·    Supporting large-scale, continuous potable water monitoring projects, including the operational scaling of 24/7 Continuous Toxic Monitoring (CTM) installations and expansion of opportunities, building on the successful Qatar deployment.

·    Further development and optimisation of CTM software and system performance, enhancing automation, reliability and scalability for utility and state-operated customers.

·    Ongoing investment in product development, including optimisation of the Company's market-leading PFAS technologies and progression of next-generation detection capabilities.

·    Investing in management infrastructure, including sales and marketing team and distribution network.

Placing

Pursuant to the Placing, a total of 133,333,333 Ordinary Shares ("Placing Shares") have been placed, conditional only on admission to trading on AIM ("Admission"), with investors at the Placing Price, representing a discount of 3.23% to the closing mid‐market price prior to the Placing of 0.775p on 19 December 2025 (being the last practicable date prior to this announcement). Each Placing Share will rank pari passu with existing Ordinary Shares.

In connection with the Placing, the Company will issue 133,333,333 warrants to investors on the basis of one (1) warrant for every one (1) Placing Share. Each warrant entitles the holder to subscribe for one additional Ordinary Share at an exercise price of 1.5p (representing a 100% premium to the Placing Price), exercisable for a period of 2 years from the date of Admission (the "Investor Warrants").

The Placing Shares represent approximately 30% of the enlarged issued share capital of the Company and together with the Broker Warrants (as described below) would represent approximately 46% of the diluted issued share capital (assuming no other warrants or options are exercised).

Turner Pope Investments (TPI) Limited ("Turner Pope" or "TPI") is acting as broker and placing agent to the Company and Singer Capital Markets Advisory LLP ("Singer Capital Markets") is acting as Nominated Adviser to the Company. Under the terms of engagement between TPI and the Company, the Company has agreed to issue TPI warrants to subscribe for 13,333,333 Ordinary Shares in connection with the Placing exercisable at the Placing Price for 5 years from the date of Admission (the "Broker Warrants"). The issue of the Broker Warrants is conditional upon Admission.

Related party transaction

Dr. Nigel Burton is investing £50,000 in the Placing, equating to 6,666,667 Placing Shares, and will hold an aggregate 16,809,502 Ordinary Shares from Admission. Dr. Nigel Burton is a director of the Company and as such is considered a related party of the Company for the purposes of the AIM Rules for Companies. The participation of Dr. Nigel Burton in the Placing constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Company's independent directors (being Bob Moore, Executive Chairman and Chief Executive Officer, and Dr. Chris Potts, Non-Executive Director), having consulted with the Company's nominated adviser, Singer Capital Markets Advisory LLP, consider that the terms of the participation of Dr. Nigel Burton in the Placing, on the same terms as other investors, are fair and reasonable insofar as the Company's shareholders are concerned.

Admission to trading

An application will be made to the London Stock Exchange plc for admission of the Placing Shares totalling 133,333,333 Ordinary Shares to trading on AIM. It is expected that admission will become effective and dealings in the Placing Shares will commence at 8.00 a.m. on or around 24 December 2025.

Total Voting Rights

Following the issue of the Placing Shares as described above, the Company's issued ordinary share capital will consist of 443,239,487 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury.

Therefore, the above figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Cash

Following completion of the Placing and after its associated expenses, the Company's net cash position is expected to be approximately £1,088,000 and the Company will have adequate working capital headroom to continue to operate for the foreseeable future.

Bob Moore, Executive Chairman and Chief Executive Officer of Metir plc, commented:

"As highlighted in the Company's recent trading update, customer demand across our instruments, reagents and testing kits continues to grow, supported by a strong international pipeline. While commercial momentum is encouraging, the pace at which we can convert this demand into revenue is currently constrained by working capital and manufacturing capacity.

"This Fundraise will enable us to accelerate instrument production, support larger-scale continuous toxic monitoring projects building on our success in Qatar, and advance several high-value technologies towards commercialisation. Together, these initiatives will strengthen our recurring revenue model and support our objective of moving the business towards sustainable profitability. We look forward to providing regular updates on the Company's progress.

"We are grateful for the continued support of existing shareholders and the confidence shown by new investors."

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This announcement contains (or may contain) certain forward-looking statements with respect to certain of the Company's and/or the Directors' current expectations and projections about future events. These statements, which sometimes use words such as "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, reflect the directors' beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by any such forward-looking statement. Statements contained in this announcement regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this announcement is subject to change without notice and neither Singer Capital Markets nor TPI nor, except as required by applicable law, the Company assumes any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein. You should not rely on forward-looking statements, which speak only as of the date of this announcement.

-      Ends -

Enquiries:

Metir plc Bob Moore, Executive Chairman and Chief Executive Officer	[phone] via TPI
Singer Capital Markets (Nominated Adviser & Joint Broker) Alex Bond / James Fischer / Anastassiya Eley	[phone]
Turner Pope Investments (TPI) Limited (Joint Broker) Andrew Thacker / Guy McDougall	[phone]

Northstar Communications (Investor Relations) Sarah Hollins

[phone]

About Metir

Metir plc is a leading global provider of fast response, mobile and point-of-use water and environmental testing technology. Through its two established trading divisions, Modern Water and Microsaic Systems a specialist in mobile PFAS monitoring, the Company develops and supplies innovative, easy-to-use solutions that deliver rapid, accurate water and liquids quality results, helping industries, utilities and regulators monitor safety and compliance in real time.

With a strong focus on data-driven insight and field-ready design, Metir's technology supports critical decision-making across sectors, including environmental monitoring, public health and industrial process management.

Headquartered in York, UK, Metir serves worldwide customers and is dedicated to advancing water testing standards through innovative, accessible solutions.

For more information, please visit: https://www.metirplc.com 

 

END